ストックスクリーナーアプリを入手
41.42
6.92%
-3.08
アフターアワーズ：
41.42
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 4.6% After Insider Selling - MarketBeat
MIRM FY2024 EPS Estimate Raised by Cantor Fitzgerald - MarketBeat
Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 2,500 Shares of Stock - MarketBeat
Mirum Pharmaceuticals SVP sells $117,752 in stock - Investing.com
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results - Simply Wall St
HC Wainwright Has Positive Estimate for MIRM FY2024 Earnings - MarketBeat
Leerink Partnrs Has Bullish Outlook for MIRM FY2024 Earnings - MarketBeat
Janus Henderson Group PLC's Strategic Adjustment in Mirum Pharma - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Mirum Pharmac - GuruFocus.com
HC Wainwright Issues Pessimistic Estimate for MIRM Earnings - MarketBeat
Mirum Pharma to Present Key Clinical Trial Data at AASLD Liver Meeting 2024 | MIRM Stock News - StockTitan
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - MSN
Mirum shares target lifted on raised sales guidance and strong LIVMARLI sales - Investing.com Canada
How To Trade (MIRM) - Stock Traders Daily
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Issues Quarterly Earnings Results, Beats Estimates By $0.15 EPS - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $50.00 - MarketBeat
Mirum Pharmaceuticals stock hits all-time high of $45.28 By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high of $45.28 - Investing.com
Mirum Pharmaceuticals Reports Strong Q3 Sales Growth - TipRanks
MIRMMirum Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Earnings call: Mirum Pharmaceuticals reports robust Q3 2024 results By Investing.com - Investing.com Australia
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 52-Week HighHere's What Happened - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by GSA Capital Partners LLP - MarketBeat
Earnings Outlook For Mirum Pharmaceuticals - Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Mirum Pharma Grants 56K Stock Options, 28K RSUs in Key Employee Retention Move | MIRM Stock News - StockTitan
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Mirum’s liver disease drug candidate gets FDA breakthrough designation - MSN
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Mirum Pharmaceuticals (MIRM) Scheduled to Post Earnings on Tuesday - MarketBeat
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by AlphaCentric Advisors LLC - MarketBeat
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 - Business Wire
Is Mirum Pharmaceuticals (NASDAQ:MIRM) Using Too Much Debt? - Simply Wall St
(MIRM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know - MSN
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting - BioSpace
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by Analysts - MarketBeat
Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth - Insider Monkey
How to Take Advantage of moves in (MIRM) - Stock Traders Daily
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
Leerink Partners Boosts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $49.00 - Defense World
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $49.00 at Leerink Partners - MarketBeat
Mirum PharmaEyeing 50% Annual Growth In 2023 - RTTNews
(MIRM) Trading Advice - Stock Traders Daily
H.C. Wainwright maintains Buy rating on Mirum shares as enrollment for key study continues - Investing.com Canada
Analyst Expectations For Mirum Pharmaceuticals's Future - Benzinga
Mirum Pharmaceuticals (NASDAQ:MIRM) Given "Buy" Rating at HC Wainwright - MarketBeat
FDA grants breakthrough status to Mirum's PBC drug By Investing.com - Investing.com Canada
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis - BioSpace
Mirum Pharmaceuticals' Volixibat Gets Breakthrough Therapy Designation from FDA - MarketWatch
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):